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1  | INTRODUCTION
Breast cancer is the most common cancer affecting women across 
the world, and the leading cause of cancer‐related death. Given the 
high incidence of breast cancer, effort has been placed on sensi‐
tive and specific screening strategies as well as the identification of 
high‐risk patients. Through these strategies and implementation of 
antihormonal agents such as tamoxifen, prevention of breast can‐
cer is possible. The NSABP P‐1 Trial showed that the use of tamox‐
ifen reduced the risk of estrogen receptor positive breast cancer by 
49% among high‐risk patients.1 As a result, tamoxifen is currently 
recommended as a chemopreventative agent for women with an el‐
evated breast cancer risk.2,3 The current indications for tamoxifen 
as chemoprevention include patients diagnosed with atypical duc‐
tal hyperplasia (ADH), atypical lobular hyperplasia (ALH), a BRCA 
mutation, lobular carcinoma in situ (LCIS), flat epithelial atypia (FEA), 
or a strong family history.4
Given the long‐term benefits of tamoxifen, young high‐risk 
women may be a patient population that stands to obtain the great‐
est benefit. Despite this potential benefit, the number of eligible 
women, particularly young women, undergoing tamoxifen chemo‐
prevention therapy is low.5 The decision to initiate tamoxifen che‐
moprevention is complex, and multiple barriers and characteristics 
associated with the utilization of this therapy have been reported.6,7 
In this study, we sought to identify factors associated with tamoxifen 
noninitiation among young patients with an increased risk for the de‐
velopment of breast cancer. With a thorough understanding of these 
deterring factors, providers may be able to help implement effective 
interventions to address these factors and increase tamoxifen initia‐
tion among young high‐risk women.
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Abstract
We sought to identify factors associated with disparities in tamoxifen utilization 
among young patients at high‐risk for developing breast cancer. We identified 67 
premenopausal, high‐risk women age 35‐45, without surgical prophylaxis, who did 
not initiate tamoxifen. Factors associated with noninitiation were examined. About 
37% of patients had no documented provider‐based discussion regarding initiation. 
Type of high‐risk diagnosis was the only factor associated with a provider‐based dis‐
cussion (P = .03). For patients offered tamoxifen, primary reasons for noninitiation 
were perceived minimal benefit (66.7%), fertility concerns (16.7%), and concerns 
about side effects (7.1%). Implementation of comprehensive educational strategies 
regarding the benefits of tamoxifen should be facilitated to improve initiation among 
young high‐risk patients.
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2  | METHODS
2.1 | Patient selection
With IRB approval, we identified women treated at Northwestern 
Memorial Hospital (Chicago, IL) who were younger than 46 years 
and received a high‐risk diagnosis (BRCA mutation, LCIS, ADH, ALH, 
FEA, strong family history) between 2007 and 2012, for whom ad‐
juvant tamoxifen was indicated, but was not initiated. Strong fam‐
ily history of breast cancer included first‐degree female relatives. A 
total of 239 patients were identified. Patients who opted for sur‐
gical prophylaxis (bilateral mastectomy, bilateral oophorectomy), 
received a cancer diagnosis, or who initiated tamoxifen use were ex‐
cluded (n = 91). Additionally, women younger than 35 years (n = 81) 
for whom tamoxifen was not indicated were excluded.
2.2 | Chart review
Patient charts were reviewed for demographics, fertility concerns, 
and high‐risk stratification. Collected data had been documented 
TA B L E  1   High‐risk breast cancer diagnosis





Family Hx 3 (4.5%)
FEA 4 (6.0%)
LCIS 12 (17.9%)
Family history of breast cancer  
Positive 46 (68.7%)
Negative 21 (31.3%)
Family history of ovarian cancer  
Positive 16 (23.9%)
Negative 51 (76.1%)
Genetic mutation status  
BRCA1+ 12 (17.9%)
BRCA2+ 9 (13.4%)
No genetic mutation 17 (25.4%)
Declined genetic testing 29 (43.3%)
History of breast biopsy  
Yes 44 (65.7%)
No 23 (34.3%)
History of breast MRI  
Yes 20 (29.9%)
No 47 (70.1%)
High‐risk breast cancer diagnosis characteristics in patients who did 
not initiate tamoxifen including the type of high‐risk diagnosis, family 
history of breast cancer, patient history of genetic testing, MRI, and/or 
biopsy.




n (%) 42 (62.7%) 25 (37.3%)  
Mean age (SD) 41.3 (2.9) 40.7 (3.2) 0.44
Diagnosis    
ADH/ALH 19 (47.6) 8 (36.0) 0.03
BRCA 1 + /2 + 8 (14.3) 13 (48.0)
Family history 3 (9.5) 0 (4.0)
FEA 2 (7.1) 2 (8.0)
LCIS 10 (21.4) 2 (4.0)
Race (%)    
White 23 (54.8) 19 (76.0) 0.47
Black 4 (9.5) 2 (8.0)
Asian 2 (4.8) 0 (0.0)
Other 4 (9.5) 2 (8.0)
Declined 9 (21.4) 2 (8.0)
Ethnicity (%)    
Hispanic 8 (19.0) 2 (8.0) 0.41
Non‐hispanic 28 (66.7) 20 (80.0)
Declined 6 (14.3) 3 (12.0)
Marital status (%)    
Single 11 (26.2) 5 (20.0) 0.67




3 (7.1) 3 (12.0)
Alcohol use (%) 25 (59.5) 16 (64.0) 0.72
Smoking (%)    
Never 30 (71.4) 21 (84.0) 0.65
Former 8 (19.0) 3 (12.0)
Current 3 (7.1) 1 (4.0)
Unknown 1 (2.4) 0 (0.0)
Insurance (%)    
None 14 (33.3) 6 (24.0) 0.26
Private 27 (64.3) 16 (64.0)
Public 1 (2.4) 3 (12.0)
Family history (%)    
None 13 (31.0) 8 (32.0) 0.61
1st degree 
relative
18 (42.9) 8 (32.0)
Non‐1st degree 
relative
11 (26.2) 9 (36.0)
Anxiety (%) 7 (16.7) 4 (16.0) 1.00
Obesity (%) 4 (9.5) 4 (16.0) 0.46
Nulliparous (%) 24 (57.1) 13 (52.0) 0.50
Abbreviations: ADH, atypical ductal hyperplasia; ALH, atypical lobular 
hyperplasia; FEA, flat epithelial atypia; LCIS, lobular carcinoma in situ; 
SD, standard deviation.
Statistically significant value is indicated in bold font.
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in the EMR through standardized formal Breast Cancer intake 
forms. Since the establishment of the Oncofertility program at 
Northwestern Memorial Hospital in 2007, a prompt was placed in 
the EMR, requiring oncologists to ask premenopausal patients about 
interest in fertility preservation prior to completing the medical re‐
cord and the initiation of therapy. This information also was collected 
and compiled from providers' notes. Reviewing oncology notes and 
cross‐referencing with pharmacies for patient's prescription data, 
tamoxifen use was also recorded. We examined the baseline demo‐
graphic characteristics for the study patients and identified patient 
reasons for tamoxifen noninitiation. We also stratified the study 
patients by their high‐risk diagnoses. A lack of documented discus‐
sion regarding tamoxifen indications or initiation were also noted. 
We performed Chi‐Square tests with a significance value of 0.05 to 
identify patient factors associated with a lack of documented discus‐
sion regarding tamoxifen initiation.
3  | RESULTS
We included a total of 67 patients in the study. The median age was 
41 (range 35‐45) and majority of the patients were white (62.7%). 
The preponderance of the patients in our study held a high‐risk 
diagnosis of ADH (29.9%) followed by LCIS (17.9%) and BRCA 1 
mutations (17.9%) (Table 1). Patients who had a high‐risk diagnosis 
from biopsy‐proven pathology and family history were categorized 
by biopsy‐proven pathology. Patients who had only a family his‐
tory of breast cancer and no pathologic or genetic diagnosis (n = 3, 
4.5%) were listed as “Family History.” Of all of the patients with a 
high‐risk diagnosis, the majority (68.7%) did have a family history 
of breast cancer. In the study population, 43.3% of patients opted 
to forgo genetic testing. Of the 38 patients that were tested, 17 
(44.7%) had no genetic mutation, 9 (23.7%) had a BRCA 2 muta‐
tion, and 12 (31.6%) had BRCA 1 mutation. Most of the patients 
in our study did not have a breast MRI (70.1%), but had breast bi‐
opsy (65.7%). Table 2 shows comparisons between characteristics 
for patients that had a documented provider discussion regarding 
tamoxifen initiation and those that did not. There were no signifi‐
cant differences in patient demographics between the two groups. 
There was an association between patients with a tissue diagnosis 
(ADH/ALH or LCIS) and a documented provider discussion about 
tamoxifen (P = .03).
3.1 | Reasons for tamoxifen noninitiation
Reasons for tamoxifen noninitiation were stratified into five catego‐
ries (Figure 1 and Figure 2). The most common reason for noninitia‐
tion was a perception of little benefit (41.8%). Despite the indications 
for tamoxifen, 37.3% of patients did not have a documented discus‐
sion with a provider regarding treatment risks and benefits. Results 
were further stratified into reasons for declining tamoxifen among 
patients who had a documented discussion. The primary reason high‐
risk women (66.7%) declined tamoxifen was perception of little bene‐
fit. Declining tamoxifen for fertility concerns (16.7%) was the second 
most prevalent reason. A relatively low number of high‐risk women 
declined tamoxifen secondary to concerns about side effects (7.1%).
4  | DISCUSSION
Considering the vast amount of data detailing the preventive ben‐
efit of tamoxifen for high‐risk patients, it is concerning that the 
most common reason for underutilization in our study was percep‐
tion of little benefit. A possible explanation could be a lack of in‐
formation provided to high‐risk patients. However, Fagerlin found 
that the perception of little benefit persisted even after provid‐
ing patients with a decision aid outlining the risks and benefits 
of tamoxifen for chemoprevention.8 These findings were similar 
to those found by Port showing that educational sessions did not 
affect patients' decisions regarding tamoxifen.9 These findings 
indicate possible discordant perceptions of tamoxifen benefit 
between patients and providers. While physicians are trained to 
practice medicine in an evidence‐based manner, patients' deci‐
sions may not be as objective. Accordingly, Donnelly found that 
patients tend to be influenced by their social groups.10 Donnelly 
also found that some women refused tamoxifen because it served 
as a constant reminder of their cancer risk.10 Thus, though an on‐
going risk of cancer may encourage some to actively participate 
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in prevention strategies, some women may approach this con‐
cern differently. To this end, Holmberg found that patients did 
not rely solely on a quantitative risk‐benefit analysis when mak‐
ing decisions.11 Instead, they incorporated their life experiences 
and approached decision‐making in a more personally meaningful 
manner. These factors can pose a challenge to providers, as the 
communication of quantifiable information may not be adequate 
to help patients make decisions regarding healthcare choices. A 
more tailored approach is warranted to ensure that the appropri‐
ate information is conveyed to the patient, which demands both 
clinical time and careful attention to individual patient concerns.
Fertility concerns are a unique aspect of the younger high‐risk 
patient population that sets this cohort apart from older postmeno‐
pausal patients. For example, despite being viable strategies, embryo 
and oocyte preservation options were offered only about 39%‐43% 
and 62%‐63%, respectively, for eligible patients with breast cancer.12 
Furthermore, contrary to data establishing safety of ovarian stimula‐
tion, 42.1% of surveyed providers agreed to or were neutral about the 
statement that ovarian stimulation for embryo/oocyte preservation 
was not safe.12 In our study, 10.4% of all patients that did not initiate 
tamoxifen chemoprevention stated their reason was fertility concerns. 
Among those patients that had a documented discussion about tamox‐
ifen with their provider, the proportion of patients reporting fertility 
concerns was 16.7%. This finding may be associated with information 
regarding the teratogenicity of tamoxifen and the years long time frame 
for tamoxifen treatment. Accordingly, a desire for future fertility is an 
independent predictor of delayed or noninitiation of tamoxifen among 
patients diagnosed with breast cancer.13 These findings underscore the 
importance of education regarding options for fertility preservation 
for patients and providers confronting tamoxifen chemoprevention. A 
F I G U R E  2   Reasons for tamoxifen noninitiation after a 

























F I G U R E  3    Schematic approach to the 
management of young patients at high‐
risk for developing breast cancer
Consulta on in survivorship clinic to 
discuss survivorship issues and risk 
lowering strategies  
Chemopreven on u izing 
tamoxifen as indicated for 
risk reduc on 
Fer ty concerns and preserva on 
Tamoxifen side effects: 
Hot flashes and depression 
 
Ini ate tamoxifen 
when pregnancy is 
completed        
(natural or ART)  
Ini ate tamoxifen, 
interrupt therapy to 
mpt pregnancy 
(natural or ART), 
resume following birth 
for 5-10 years 
Ini ate tamoxifen and 
con nue for 5-10 
years, followed by 
mp ng pregnancy 
(natural or ART)  
Life style modifica ons:                 
1) Weight loss                                    
2) Low fat diet                                    
3) Low alcohol intake                       
4) Exercise regularly                         
5) Smoking cessa on 
Pa t with high-risk for developing 
breast cancer diagnosis 
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hiatus from tamoxifen to allow patients to become pregnant is also being 
studied.14 Early referral to a provider with specialization in reproductive 
endocrinology to facilitate the fertility preservation discussion is critical.
Another aspect of patient perceptions about tamoxifen identified 
in our study was the concern about side effects. Bober found a de‐
crease in tamoxifen initiation among women of all ages concerned with 
side effects.15 Donnelly found the perceived impact of side effects 
to be a common theme among young patients accepting or declining 
tamoxifen.10 Interventions to minimize the side effects of tamoxifen 
utilizing medications such as venlafaxine could decrease discontinua‐
tion rates and help alleviate patient concerns regarding side effects.16
In terms of patient‐physician communication, more than a third 
of the patients did not have a documented discussion with their pro‐
vider regarding tamoxifen. A physician‐led discussion is a major con‐
tributor to initiation of tamoxifen among patients, as the physician 
recommendation of tamoxifen has been associated with initiation.15 
This effect also occurs at the primary care level, as a study by Taylor 
and Taguchi found the opinion of the family physician to play a role 
in the patients' decision to start tamoxifen.17 A lack of discussion by 
physicians may also be the result of a lack of provider knowledge.18 
Kaplan found that a deficit in training was a barrier in tamoxifen pre‐
scription.19 That work also found that breast cancer risk reduction 
practices varied significantly based on the specialty of the primary 
treating provider.19 Collectively, these findings indicate areas for 
standardization of information and improved medical education re‐
garding the nature of physician discussions, bias, and inherent per‐
ceptions about the risk/benefit associated with tamoxifen.
Patient decision‐making is a complex process, and physicians must 
ensure that the patient's decision is informed. For this purpose, a multi‐
disciplinary approach may be warranted in the management of young 
high‐risk patients. Concerns over fertility or side effects could be al‐
leviated through a comprehensive discussion and education. Through 
a team approach including oncologists, surgeons, and oncofertility 
specialists, many concerns about tamoxifen could be addressed. We 
propose an algorithm for the management of these patients that may 
help fill the gaps in communication between providers and patients 
(Figure 3). Patient decision‐making is a highly individualized process. 
Providers should be equipped to discuss evidence‐based data while 
also offering a patient‐centered approach to care to ensure that pa‐
tients are enabled to make most informed decisions possible.
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